BAC vs LLY: Which Is the Better Buy?
Side-by-side comparison of Bank of America Corporation and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-17.
Bank of America Corporation · Financial Services
$59.50
-45.0% upside to fair value
Grade C
VS
Eli Lilly and Company · Healthcare
$1,179.09
+31.7% upside to fair value
High Conviction
Grade A
High Quality
QuantHub Verdict
LLY has more upside to fair value
(+31.7%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
BAC |
LLY |
| Current Price |
$59.50 |
$1,179.09 |
| Fair Value Estimate |
$32.73 |
$1,552.32 |
| Upside to Fair Value |
-45.0%
|
+31.7%
|
| Market Cap |
$422.2B |
$1,110.4B |
| Forward P/E |
14.6x
|
—
|
| EV / EBITDA |
13.3x
|
34.3x
|
| Price / Sales |
2.4x
|
14.6x
|
| Price / FCF |
7.5x
|
77.7x
|
| Revenue Growth YoY |
-35.6%
|
+55.5%
|
| Gross Margin |
63.2%
|
83.5%
|
| Operating Margin |
22.9%
|
45.9%
|
| Return on Equity |
10.5%
|
101.3%
|
| Dividend Yield |
0% |
0.55% |
| FCF Yield |
13.4%
|
1.29%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
Bank of America Corporation operates as a diversified bank within the financial services sector, offering a broad range of banking and financial products. The business quality is medium, supported by a 10.5% return on equity and solid margins, but recent revenue declined sharply by 35.6% in the most recent quarter, indicating top-line pressure. Despite earnings growth of 16.1% in the same period,…
Eli Lilly is a global biopharma company whose exceptionally profitable cardiometabolic franchises, led by Mounjaro and Zepbound, are driving a high-quality growth phase: revenue rose 55.5% year over year and earnings rose 168.0% year over year in the most recent quarter, while gross, operating, and net margins were 83.5%, 45.9%, and 35.0%, respectively. Business quality is high because tirzepatid…
Accumulation Zones
| Metric |
BAC |
LLY |
| Zone Low |
$24.55 |
$1,164.24 |
| Zone High |
$27.82 |
$1,319.47 |
| In Buy Zone? |
No
|
Yes
|